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Transluminal placement of endovascular stent-
grafts is a less invasive alternative to open repair for
the treatment of descending aortic aneurysms in
selected cases.1 During stent-graft deployment,
proximal hypertension occurs, which may adversely
affect myocardial function2 and may cause distal
displacement or malpositioning of the stent. Present
strategies to avoid proximal hypertension include
temporary asystole induced with adenosine,3,4 the
Valsalva maneuver (hyperventilation followed by
inspiration hold),5 vena cava occlusion with bal-
loon,6 or electrically induced ventricular fibrilla-
tion.7 None of these methods of blood pressure
control are feasible in awake patients. However,
endovascular stenting of the thoracic aorta can be
performed under local anesthesia,8 because surgery
is limited to vascular access to the femoral artery.
Moreover, self-expandable stent-grafts allow short
occlusion times of the thoracic aorta of less than 30
seconds. We report on the use of intravenous nitro-
glycerin to control blood pressure in four consecu-
tive patients who underwent endovascular stent-
grafting of the descending thoracic aorta.
CASE REPORTS
Case 1. Preoperative investigations in a 62-year-old
man (weight, 73 kg) with a medical history of left scapular
pain that radiated to the left arm revealed a 2 × 5 cm large
aneurysm of the descending aorta in the thoracic comput-
ed tomography scan. For prognostic reasons, the decision
was made to perform an operation on the aneurysm, which
was considered suitable for endovascular repair.
On the day of the operation, the patient was given pre-
medication with oral midazolam, and his previous medica-
tion with β blockers was continued. Monitoring consisted
of a 12-lead electrocardiogram, pulse oximetry, and a radi-
al artery, central venous line, and balloon-tipped pul-
monary artery catheter (indication depended on comor-
bidity) introduced through the right jugular vein under
local anesthesia. Printouts of arterial, central venous, and
pulmonary arterial blood pressures were continuously per-
formed. After infiltration of the right groin with a 1% solu-
tion of lidocaine (5 mg/kg body weight), the right com-
mon femoral artery was prepared for introduction of the
endograft (Excluder 34 × 12; Prograft Medical Inc,
Sunnyvale, Calif). Central venous bolus injections of nitro-
glycerin in increasing doses (25, 50, 100, and 150 µg) were
given to titrate mean arterial blood pressure to a predeter-
mined target value of 60 mm Hg. The endovascular stent-
graft was then positioned in the descending aorta under
fluoroscopy. When the stent was properly positioned,
another bolus of 150 µg nitroglycerin was administered,
which decreased mean arterial pressure from 83 to 63 mm
Hg (Fig 1). The surgeon was asked to deploy the self-
expandable stent, and the mean blood pressure rose from
63 to 77 mm Hg. To model the stent to the aortic wall, the
balloon had to be inflated and deflated four times. Another
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50 µg of nitroglycerin was necessary during this procedure
to keep the blood pressure between 62 and 82 mm Hg
(Fig 1). No significant rise in pulmonary arterial pressure
occurred. The operation lasted 45 minutes. Subsequently
the patient was sent to the ward and discharged from the
hospital on postoperative day 3.
Case 2. In a 68-year-old man (weight, 94 kg) with a
history of hypertension, a routinely performed chest radio-
graph showed an aneurysm of the descending aorta that
was 5.6 cm in diameter and suitable for endoluminal stent-
graft repair. The anesthetic procedure was identical to case
1. A dose of 150 µg of nitroglycerin was needed to lower
the mean blood pressure from 95 to 60 mm Hg. Before
the endograft was deployed (Excluder 34 × 15; Prograft
Medical Inc), 200 µg of nitroglycerin was given, and the
mean arterial pressure fell to 61 mm Hg. The stent was
then deployed, and the blood pressure rose to 78 mm Hg.
The balloon had to be inflated and deflated five times to
model the stent-graft to the aortic wall, and each time 100
to 250 µg of nitroglycerin was administered. The blood
pressure rose to a maximum value of 87 mm Hg. After the
operation, the patient was taken to the ward and dis-
charged from the hospital on postoperative day 5. 
Case 3. An aneurysm of the descending thoracic
aorta, 7.8 cm in diameter, was found in a 79-year-old
woman (weight, 68 kg) with a history of hypertension and
vascular disease, who had previously undergone an
aorto–bi-iliacal graft. Again, the anesthetic procedure was
the same as described earlier, except for a continuous infu-
sion of nitroglycerin (50 µg/min), which was started at
the beginning of the operation because of the known his-
tory of coronary artery disease. After an intravenous bolus
of 50 µg nitroglycerin, the arterial blood pressure fell from
105 to 78 mm Hg. As in the earlier cases, mean arterial
blood pressure remained below 90 mm Hg, although
more and increasingly larger doses of nitroglycerin (total
dose, 3.6 g) were needed during stent-graft deployment
and modeling (Talent, Sunrise, Fla). After the operation,
the patient was sent to the ward and discharged from the
hospital on postoperative day 4.
Case 4. An aneurysm of the descending aorta, 5 cm
in diameter, and a 90% stenosis of the right coronary artery
was found in a 67-year-old patient (weight, 63 kg) with a
long smoking history, who had previously undergone an
aorto–bi-iliacal graft and a right femorocrural bypass graft-
ing procedure with multiple reinterventions. The decision
was made to perform a graft from the right mammarian
artery to the right coronary artery without cardiopul-
Fig. 1. A, Blood pressure curve after a bolus of 150 µg nitroglycerin intravenously (to lower
blood pressure for stent deployment). B, Blood pressure curve during stent deployment. 
C, Blood pressure curve during modeling of the stent-graft to the aortic wall (three times).
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monary bypass and to implant a thoracic endovascular stent-
graft. Anesthesia was obtained with propofol and sufentanil.
Monitoring included transesophageal echocardiography in
addition to the measures taken in cases 1 through 3. Blood
pressure was maintained between 60 and 90 mm Hg with
bolus injections of 50 to 75 µg nitroglycerin throughout
the stent-grafting procedure (Talent). After the operation,
the patient remained in the intensive care unit for 2 days and
was discharged on postoperative day 13. 
DISCUSSION
In contrast to open surgery of thoracic descending
aortic aneurysms, repair with endovascular stent-grafts
can be performed under local anesthesia. For stent
deployment, several methods have been described to
control blood pressure and hence to avoid displace-
ment of the stent, damage to the aorta (dissection or
rupture), and myocardial ischemia or infarction2:
induction of ventricular fibrillation,7 vena cava occlu-
sion with balloon,6 the Valsalva maneuver,5 and inten-
tional asystole with intravenous bolus injections of
adenosine.3,4 None of these methods are suitable for
endoluminal stent-graft repair performed under local
anesthesia. Additional disadvantages of intentional
asystole with adenosine or ventricular fibrillation are a
complete stop of the normal perfusion (especially of
the heart and the brain), the possibility of ventricular
dilation, and the difficulty in predicting the time of
asystole. Moreover, in our experience, it is not neces-
sary to completely stop aortic flow. Nitroglycerin,
administered as bolus injection, induces a rapid and
brief (1-4 minutes) decrease in blood pressure mediat-
ed by the formation of nitric oxide in vascular smooth
muscle. Myocardial oxygen requirements are dimin-
ished by reduction of ventricular preload and after-
load.9 Thus nitroglycerin seems to be a suitable and
safe drug to induce a brief decrease in blood pressure
during stent deployment. Alternatively, other short-
acting vasodilators such as sodium nitroprusside may
be used, but the anti-ischemic effect of nitroglycerin
may be beneficial in this patient population. In all four
cases presented here, mean arterial blood pressure
remained between 60 and 90 mm Hg during the
stent-graft procedure, and we saw no adverse cardiac
effects. In all our patients, β-blocker therapy was con-
tinued until the morning of surgery and, in contrast to
Dake et al,10 there was no indication for additional
intraoperative application of β blockers. Titration of
intravenous boli of nitroglycerin was performed in
each patient before stent-graft deployment to reach a
target blood pressure of 60 mm Hg. The doses need-
ed to achieve this goal ranged from 50 to 250 µg.
Close cooperation between the anesthetist and the sur-
geon is of utmost importance for the timing of the
nitroglycerin application, stent-graft deployment, and
stent modeling through balloon inflation. Tolerance to
nitroglycerin may occur and is a function of dosage
and frequency of administration.9 In case 3 (a patient
with a known history of coronary artery disease), an
intravenous infusion of nitroglycerin was started at the
beginning of the operative procedure to prevent
myocardial ischemic episodes. Increasingly higher
doses of nitroglycerin had to be administered to keep
blood pressure below 90 mm Hg during modeling of
the stent to the aortic wall. Headache is a common
and untoward response to nitroglycerin but did not
occur in our patients nor did tachycardia, vomitus,
flush, or allergy. Methemoglobin was not measured
but is unlikely to rise in that dose range. Distal migra-
tion of the stent, necessitating reintervention,
occurred in none of the four patients; neither did it
occur in eight patients who underwent operation ear-
lier, before establishing a strict nitroglycerin protocol.
According to our experience, blood pressure con-
trol during deployment and modeling of thoracic
endovascular stent-grafts with nitroglycerin is safe and
easy to perform in patients both under general and
local anesthesia. It is less invasive than previously rec-
ommended methods, such as temporary asystole,
vena cava occlusion with balloon, or induced ventric-
ular fibrillation. 
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